Published : Mar-2020
No. of Pages : 121
1.1 List of Tables
1.2 List of Figures
2 Pneumococcal Vaccines: Executive Summary
2.1 Sales
2.2 R&D Strategies
2.3 Unmet Needs
2.4 Remaining Opportunities for New Entrants
2.5 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
5 Epidemiology
6 Immunization Recommendations
7 Competitive Assessment
7.1 Overview
8 Unmet Needs and Opportunity Assessment
9 Pipeline Assessment
10 Current and Future Players
11 Market Outlook
12 Appendix
List of Tables
Table 1: Pneumococcal Vaccines Key Metrics in the 9MM
Table 2: Risk Factors and Comorbidities for Invasive Pneumococcal Disease
Table 3: 7MM, Pediatric Pneumococcal Vaccination Rate Trends (%)
Table 4: 6MM, Elderly Pneumococcal Vaccination Rate Trends (%)
Table 5: 3GM, Pediatric Pneumococcal Vaccination Rate Trends (%)
Table 6: 3GM, Elderly Pneumococcal Vaccination Rate Trends (%)
Table 7: Vaccination Guidelines for Pneumococcal Disease
Table 8: Leading Pneumococcal Vaccines
Table 9: Pfizer's Pneumococcal Vaccine Portfolio Assessment, 2020
Table 10: Merck's Pneumococcal Vaccine Portfolio Assessment, 2020
Table 11: Pneumococcal Vaccine Market - Global Drivers and Barriers, 2018-2028
Table 12: Key Events Impacting Sales for Pneumococcal Vaccines in the US, 2018-2028
Table 13: Pneumococcal Vaccines Market - Drivers and Barriers in the US, 2018-2028
Table 14: Key Events Impacting Sales for Pneumococcal Vaccines in the 5EU, 2018-2028
Table 15: Pneumococcal Vaccines Market - Drivers and Barriers in the 5EU, 2018-2028
Table 16: Key Events Impacting Sales for Pneumococcal Vaccines in Japan, 2018-2028
Table 17: Pneumococcal Vaccines Market - Global Drivers and Barriers in Japan, 2018-2028
Table 18: Key Events Impacting Sales for Pneumococcal Vaccines in Australia, 2018-2028
Table 19: Pneumococcal Vaccines Market - Global Drivers and Barriers in Australia, 2018-2028
Table 20: Key Events Impacting Sales for Pneumococcal Vaccines in South Korea, 2018-2028
Table 21: Pneumococcal Vaccines Market - Global Drivers and Barriers in South Korea, 2018-2028
Table 22: Key Historical and Projected Launch Dates for Pneumococcal Vaccines
Table 23: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global Sales Forecast by Country for Pneumococcal Vaccines in 2018 and 2028
Figure 2: Analysis of the Company Portfolio Gap in Pneumococcal Vaccines During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pneumococcal Vaccines that GlobalData Expects to Be Licensed for the Treatment of Pneumococcal Vaccines During the Forecast Period
Figure 4: A Schematic Diagram of the Virulence Factors of S. pneumoniae
Figure 5: The Life Cycle of S. pneumoniae and the Pathogenesis of Pneumococcal Disease
Figure 6: 7MM, Diagnosed Incidence of IPD, Both Sexes, All Ages, 2008?2028
Figure 7: 3GM, Diagnosed Incidence of IPD, Both Sexes, All Ages, 2008-2028
Figure 8: 7MM, Sources Used for the Pneumococcal Vaccinated Pediatric Population
Figure 9: 6MM, Sources Used for the Pneumococcal Vaccinated Elderly Population
Figure 10: 7MM, Sources Used for the Diagnosed Incident Cases of IPD
Figure 11: 3GM, Sources Used for the Pneumococcal Vaccinated Pediatric Population
Figure 12: 3GM, Sources Used for the Pneumococcal Vaccinated Elderly Population
Figure 13: 3GM, Sources Used for the Diagnosed Incident Cases of IPD
Figure 14: 7MM, Pneumococcal Vaccinated Pediatric Population, Both Sexes, 2018
Figure 15: 3GM, Pneumococcal Vaccinated Pediatric Population, Both Sexes, 2018
Figure 16: 6MM, Pneumococcal Vaccinated Elderly Population, Both Sexes, 2018
Figure 17: 3GM, Pneumococcal Vaccinated Elderly Population, Both Sexes, 2018
Figure 18: 7MM, Diagnosed Incident Cases of IPD, Both Sexes, All Ages, 2018
Figure 19: 3GM, Diagnosed Incident Cases of IPD, Both Sexes, All Ages, 2018
Figure 20: 7MM, Age-Specific Diagnosed Incident Cases of IPD, Men and Women, 2018
Figure 21: 3GM, Age-Specific Diagnosed Incident Cases of IPD, Men and Women, N, 2018
Figure 22: Pneumococcal Vaccination Schedule for the 9MM
Figure 23: Unmet Needs and Opportunities in Pneumococcal Vaccines
Figure 24: Overview of the Development Pipeline for Pneumococcal Vaccines
Figure 25: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for Pneumococcal Vaccination in the 9MM During the Forecast Period
Figure 26: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Pneumococcal Disease During the Forecast Period
Figure 27: Analysis of the Company Portfolio Gap in Pneumococcal Vaccination During the Forecast Period
Figure 28: Global (9MM) Sales Forecast by Country for Pneumococcal Vaccines in 2018 and 2028
Figure 29: Sales Forecast by Class for Pneumococcal Vaccines in the US in 2018 and 2028
Figure 30: Sales Forecast by Class for Pneumococcal Vaccines in the 5EU in 2018 and 2028
Figure 31: Sales Forecast by Class for Pneumococcal Vaccines in Japan in 2018 and 2028
Figure 32: Sales Forecast by Class for Pneumococcal Vaccines in Australia in 2018 and 2028
Figure 33: Sales Forecast by Class for Pneumococcal Vaccines in South Korea in 2018 and 2028
